Business Standard

A COMMERCIAL FEATURE

What's this ?

Commercial Feature is a Business Standard Digital Marketing Initiative.

The Editorial/Content team at Business Standard has not contributed to writing or editing these articles.

For further information, please write to assist@bsmail.in

Jubilant to acquire radiopharmacy business of US-based Triad Isotopes

Triad operates the second largest radiopharmacy network in the US with more than 50 pharmacies

Rakesh Rao  |  Mumbai 

Triad Isotopes
Triad Isotopes

The Noida-based Pharma Limited (JPL), a wholly owned subsidiary of Life Sciences Limited, has agreed to acquire the business of the US-based for an undisclosed amount. For this, an asset purchase agreement was signed by JPL with and its parent, Isotope Holdings Inc.

The acquisition will be funded through JPL’s internal accruals and is likely to be earnings accretive in the first full year of operations.

Triad recorded revenues in excess of $ 225 million in 2016 with positive EBITDA and operates the second largest network in the US with more than 50 pharmacies, distributing products to the largest national GPOs, regional health systems, stand-alone imaging centres, cardiologists and hospitals. 

The acquisition is a strategic fit to Jubilant’s niche business and will provide with direct access to hospital networks with ability to deliver more than 3 million patient doses annually through approximately 1,700 customers. The acquisition will facilitate forward integrate in the radiopharmaceutical business, thereby helping it better directly serve healthcare providers and their patients with high quality radiopharmaceutical products.

The US market accounts for approximately 70 percent of the Pharma’s business sales, with Canada accounting for close to 20 percent sales and the rest of the revenues coming from markets in Europe, Latin America and Asia. has been further strengthening its business in the US. 

In January this year, DraxImage Inc (JDI), the Montreal (Canada) based wholly-owned subsidiary of Pharma, signed long term contracts with distribution networks in the US for supply of products used for diagnostic and therapeutic procedures for thyroid, myocardial perfusion, lung, kidney and bone scans.

Pharma’s business develops, manufactures and markets a portfolio of products that enable physicians to deliver personalised healthcare to their patients around the globe. Its core products primarily serve patients with cardiac, thyroid and lung disease providing reliable high quality imaging agents and patient specific therapies for procedures.

RECOMMENDED FOR YOU

Jubilant to acquire radiopharmacy business of US-based Triad Isotopes

Triad operates the second largest radiopharmacy network in the US with more than 50 pharmacies

Triad operates the second largest radiopharmacy network in the US with more than 50 pharmacies
The Noida-based Pharma Limited (JPL), a wholly owned subsidiary of Life Sciences Limited, has agreed to acquire the business of the US-based for an undisclosed amount. For this, an asset purchase agreement was signed by JPL with and its parent, Isotope Holdings Inc.

The acquisition will be funded through JPL’s internal accruals and is likely to be earnings accretive in the first full year of operations.

Triad recorded revenues in excess of $ 225 million in 2016 with positive EBITDA and operates the second largest network in the US with more than 50 pharmacies, distributing products to the largest national GPOs, regional health systems, stand-alone imaging centres, cardiologists and hospitals. 

The acquisition is a strategic fit to Jubilant’s niche business and will provide with direct access to hospital networks with ability to deliver more than 3 million patient doses annually through approximately 1,700 customers. The acquisition will facilitate forward integrate in the radiopharmaceutical business, thereby helping it better directly serve healthcare providers and their patients with high quality radiopharmaceutical products.

The US market accounts for approximately 70 percent of the Pharma’s business sales, with Canada accounting for close to 20 percent sales and the rest of the revenues coming from markets in Europe, Latin America and Asia. has been further strengthening its business in the US. 

In January this year, DraxImage Inc (JDI), the Montreal (Canada) based wholly-owned subsidiary of Pharma, signed long term contracts with distribution networks in the US for supply of products used for diagnostic and therapeutic procedures for thyroid, myocardial perfusion, lung, kidney and bone scans.

Pharma’s business develops, manufactures and markets a portfolio of products that enable physicians to deliver personalised healthcare to their patients around the globe. Its core products primarily serve patients with cardiac, thyroid and lung disease providing reliable high quality imaging agents and patient specific therapies for procedures.

image
Business Standard
177 22

Jubilant to acquire radiopharmacy business of US-based Triad Isotopes

Triad operates the second largest radiopharmacy network in the US with more than 50 pharmacies

The Noida-based Pharma Limited (JPL), a wholly owned subsidiary of Life Sciences Limited, has agreed to acquire the business of the US-based for an undisclosed amount. For this, an asset purchase agreement was signed by JPL with and its parent, Isotope Holdings Inc.

The acquisition will be funded through JPL’s internal accruals and is likely to be earnings accretive in the first full year of operations.

Triad recorded revenues in excess of $ 225 million in 2016 with positive EBITDA and operates the second largest network in the US with more than 50 pharmacies, distributing products to the largest national GPOs, regional health systems, stand-alone imaging centres, cardiologists and hospitals. 

The acquisition is a strategic fit to Jubilant’s niche business and will provide with direct access to hospital networks with ability to deliver more than 3 million patient doses annually through approximately 1,700 customers. The acquisition will facilitate forward integrate in the radiopharmaceutical business, thereby helping it better directly serve healthcare providers and their patients with high quality radiopharmaceutical products.

The US market accounts for approximately 70 percent of the Pharma’s business sales, with Canada accounting for close to 20 percent sales and the rest of the revenues coming from markets in Europe, Latin America and Asia. has been further strengthening its business in the US. 

In January this year, DraxImage Inc (JDI), the Montreal (Canada) based wholly-owned subsidiary of Pharma, signed long term contracts with distribution networks in the US for supply of products used for diagnostic and therapeutic procedures for thyroid, myocardial perfusion, lung, kidney and bone scans.

Pharma’s business develops, manufactures and markets a portfolio of products that enable physicians to deliver personalised healthcare to their patients around the globe. Its core products primarily serve patients with cardiac, thyroid and lung disease providing reliable high quality imaging agents and patient specific therapies for procedures.

image
Business Standard
177 22